Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview.
about
Polygonum viviparum L. induces vasorelaxation in the rat thoracic aorta via activation of nitric oxide synthase in endothelial cells.Methylene blue modulates transendothelial migration of peripheral blood cells.Nitric oxide regulates vascular adaptive mitochondrial dynamics.Chronic inhibition of PPAR-γ signaling induces endothelial dysfunction in the juvenile lambThe chemistry and biology of soluble guanylate cyclase stimulators and activators.Depression in Cardiovascular Patients in Middle Eastern Populations: A Literature Review.Wall stretch and thromboxane A₂ activate NO synthase (eNOS) in pulmonary arterial smooth muscle cells via H₂O₂ and Akt-dependent phosphorylation.NAD(P)H:quinone oxidoreductase 1 activation reduces blood pressure through regulation of endothelial nitric oxide synthase acetylation in spontaneously hypertensive rats.Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies.REM sleep deprivation induces endothelial dysfunction and hypertension in middle-aged rats: Roles of the eNOS/NO/cGMP pathway and supplementation with L-arginineInhibitory role of S-nitrosoglutathione in the aggregation of frozen platelets, and its effect on the expression of membrane glycoproteins.Proteomics reveals potential non-neuronal cholinergic receptor-effectors in endothelial cells.The sGC stimulator riociguat inhibits platelet function in washed platelets but not in whole blood.Modulation of inducible nitric oxide synthase (iNOS) expression and cardiovascular responses during static exercise following iNOS antagonism within the ventrolateral medulla.The Restorative Effects of Eucommia ulmoides Oliver Leaf Extract on Vascular Function in Spontaneously Hypertensive Rats.Hypertension: a systemic key to understanding local keloid severity.
P2860
Q33647334-53D607B3-5CFE-4491-9100-2A34D52BD0DAQ35067725-68F0346B-4749-47AD-8CE8-AC19A580D635Q36923959-F6DADC6F-7CE1-4BEC-A9FC-94D0464E3E23Q37414446-64A97FF7-4EED-4E34-A010-52A4160A4B86Q38130465-BE7249CB-1336-4691-863A-3CD224876C22Q38219811-49BAE289-CA36-49ED-A794-1C0AA5D1DB44Q38806650-62BA4176-2C9A-4FD0-982C-8AFB6D2FF395Q38982506-644F1D9B-F5E7-406A-97DC-10D041565765Q41147581-59FAF642-226E-4FC7-832E-9200AAC98C2EQ41413915-328671C6-8EC0-46F9-B416-CB2A6B6F4784Q41821122-A62E024B-5638-4BC8-AE00-52613BAC9C5AQ41922431-52C4A4C2-6194-41B7-9DF5-6EA50FD8775AQ43119916-C30C55A1-92ED-47C5-BD16-A01D89B06B12Q47811794-F55C899C-F847-4238-A760-040079C294B2Q53236554-438CC268-69AB-4B7C-AE1D-638C61BFCA71Q53599537-63BCB90D-FABC-44F5-90A1-191ECFF71D85
P2860
Cardiovascular therapeutics targets on the NO-sGC-cGMP signaling pathway: a critical overview.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Cardiovascular therapeutics ta ...... pathway: a critical overview.
@en
type
label
Cardiovascular therapeutics ta ...... pathway: a critical overview.
@en
prefLabel
Cardiovascular therapeutics ta ...... pathway: a critical overview.
@en
P2093
P1433
P1476
Cardiovascular therapeutics ta ...... pathway: a critical overview.
@en
P2093
Alfredo J Rodrigues
Andrea C Celotto
Edwaldo E Joviliano
Patricia M Evora
Paulo Roberto B Evora
P304
P356
10.2174/138945012802002348
P577
2012-08-01T00:00:00Z